The Trulicity pen -- an injectable drug for patients to manage their type 2 diabetes -- has been around for quite some time.
Trials of Trulicity alone show it produces a 1.4 reduction from a mean baseline HbA1C of 8.1%. However it remains difficult to persuade patients to move to injectable GLP-1 therapies despite their ...